ACR 2022 Tweet by Richard Conway

This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

2026 EULAR Preview Beyond BMI: Altered Body Composition in Rheumatoid Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman’s World: Women's Health in Rheumatic Disease Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Doctor's Orders or Patient's Choice: BACH study findings…